PARIS--(BUSINESS WIRE)--Regulatory News:
Ipsen (ISIN:FR0010259150) (Paris:IPN) and MSD today announced the signing of a co-marketing agreement under which MSD will grant Ipsen the marketing rights in France for AdrovanceTM, a fixed combination of alendronate sodium and cholecalciferol (vitamin D3), indicated for the treatment of postmenopausal osteoporosis in patients at risk of vitamin D deficiency.
